MetaCap

Immix Biopharma (IMMX) vs Janux Therapeutics (JANX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Immix Biopharma (IMMX) has outperformed Janux Therapeutics (JANX) over the past year, gaining 60.7% versus a loss of 65.0%. Janux Therapeutics is the larger company by market cap ($616.7 million vs $583.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMMX+60.74%JANX-65.00%
+249%+85%-80%
Nov 21, 20251 yearNov 20, 2026
IMMX+74.00%JANX-49.65%
+265%+85%-94%
Dec 13, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMMX versus JANX key metrics
MetricIMMXJANX
Share price$6.96$10.08
Market cap$583.33M$616.73M
1-day change-1.14%-2.04%
YTD return+33.08%-26.96%
1-year return+60.74%-65.00%
5-year return—-42.92%
EPS (TTM)$-0.83$-1.59
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$10.00M
Revenue growth (YoY)—-5.55%
Net income (latest FY)$-29.40M$-113.63M
Operating margin—-1576.67%
Net margin—-1136.25%
52-week high$15.10$35.34
52-week low$3.78$10.05
Distance from 52-week high-53.91%-71.48%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+243.82%+228.77%
Average volume1.45M961.56K
Shares outstanding83.81M61.18M
Employees21114
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IMMX has outperformed JANX by 125.7 percentage points over the past year.

About Immix Biopharma

IMMX stock →

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

About Janux Therapeutics

JANX stock →

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 114 employees

IMMX vs JANX FAQ

Which is bigger, Immix Biopharma or Janux Therapeutics?

Janux Therapeutics (JANX) is larger, with a market capitalization of $616.73M compared with $583.33M for Immix Biopharma (IMMX).

Which stock has performed better over the past year, IMMX or JANX?

IMMX returned +60.74% over the past 12 months, compared with -65.00% for JANX (price return, excluding dividends). Past performance does not predict future results.

Are Immix Biopharma and Janux Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons